Pharmaceuticals company Solara Active Pharma Sciences announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Q4 Revenues at Rs 2,790 million; Q4 Gross Margin at Rs 1,605 million (57.5%); Q4 EBITDA at Rs 510 million (18.3%); FY25 Financial Highlights: FY25 Revenues at Rs 12,921 million vs Rs 12,943 million in FY24; Flat YoY FY25 Gross Margin at Rs 6,649 million (51.5%) vs Rs 4,891 million (37.8%) in FY24; improvement by 1,370 bps YoY FY25 EBITDA at Rs 2,138 million (16.5%) vs. negative Rs 917 million (-7%) in FY24; significant improvement by 2,360 bps YoY Sandeep Rao, MD & CEO stated: "FY25 was a Reset year for Solara. While we regrettably missed our guidance both on Revenues and EBITDA, we continued to focus on profitable high margin and high quality business which led to Gross Margin expansion from 37.8% in FY24 to 51.5% in FY25 and EBITDA margin expansion from -7.1% in FY24 to 16.5% in FY25. The miss on the Revenue and EBITDA guidance is attributable to intense competition on the Ibuprofen range of products. We continued to do better than expected on the remainder of our portfolio. Our product mix continues to be healthy with a majority of Revenues coming from the Regulated markets. Going ahead, we will continue our ongoing actions on improving profitability through cost improvement programs, operating cost optimization, optimizing working capital and debt as we pivot the organization from reset to growth." Result PDF